Do not administer Vyvanse during or within 14 days following the administration of MAOI [see, selegiline, isocarboxazid, phenelzine, tranylcypromine. Patients were observed for relapse (treatment failure) during the 6-week double-blind phase. Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included palpitations, diarrhea, nausea, decreased appetite, dizziness, agitation, depression, paranoia and restlessness. Si vous avez l’impression de manger du bonbon (au sens figuré bien sûr), c’est que le dosage n’est pas suffisant. De plus, Vyvanse est un médicament à effet prolongé. Vyvanse is a brand name for a drug that contains lisdexamfetamine. Patients Ages 6 to 17 Years Old: Maintenance Treatment in ADHD. Take Vyvanse by mouth in the morning with or without food; avoid afternoon doses because of the potential for insomnia. Weight Loss and Slowing Growth Rate in Pediatric Patients with ADHD. Adverse Reactions Associated with Discontinuation of Treatment in BED Clinical Trials. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. L’atomoxétine (Strattera®) est un médicament non stimulant utilisé pour traiter les troubles d'hyperactivité avec déficit de l'attention (THADA). For more information ask your doctor or pharmacist. Advise patients to store Vyvanse in a safe place, preferably locked, to prevent abuse. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Your doctor may sometimes stop Vyvanse treatment for a while to check your ADHD or your BED symptoms. Keep Vyvanse and all medicines out of the reach of children. The exposure (Cmax and AUCinf) of dextroamphetamine is similar between Vyvanse chewable tablet and Vyvanse capsule. Efficacy assessments occurred at the end of each week, using the Permanent Product Measure of Performance (PERMP), a skill-adjusted math test that measures attention in ADHD. Neither food (a high fat meal or yogurt) nor orange juice affects the observed AUC and Cmax of dextroamphetamine in healthy adults after single-dose oral administration of 70 mg of Vyvanse capsules. The parent drug, lisdexamfetamine, does not bind to the sites responsible for the reuptake of norepinephrine and dopamine in vitro. Medically reviewed by Drugs.com. Adverse Reactions Occurring at an Incidence of ≥5% or More Among Vyvanse Treated Patients with ADHD in Clinical Trials. Individual patient response to amphetamines varies widely. In the controlled adult trial (Study 7), mean weight loss after 4 weeks of therapy was 2.8 pounds, 3.1 pounds, and 4.3 pounds, for patients receiving final doses of 30 mg, 50 mg, and 70 mg of Vyvanse, respectively, compared to a mean weight gain of 0.5 pounds for patients receiving placebo. Following single-dose oral administration of Vyvanse capsule (30 mg, 50 mg, or 70 mg) in patients ages 6 to 12 years with ADHD under fasted conditions, Tmax of lisdexamfetamine and dextroamphetamine was reached at approximately 1 hour and 3.5 hour post dose, respectively. All rights reserved. Active ingredient: lisdexamfetamine dimesylate. Amphetamine (d- to l-enantiomer ratio of 3:1) did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day. Advise patients of the potential fetal effects from the use of Vyvanse during pregnancy. Long-term neurochemical and behavioral effects have also been reported in animal developmental studies using clinically relevant doses of amphetamine [see Data]. Before using Vyvanse, tell your doctor if you have any pre-existing health conditions or if you take any other medications. (lisdexamfetamine The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate. Lisdexamfetamine is a pro-drug of dextroamphetamine. If that happens, tell your doctor. The most common side effects of Vyvanse in ADHD include: The most common side effects of Vyvanse in BED include: This Medication Guide has been approved by the U.S. Food and Drug Administration, ANALYSIS(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120), API MANUFACTURE(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120), ANALYSIS(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107), MANUFACTURE(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107), PACK(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107), ANALYSIS(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107), ANALYSIS(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120), MANUFACTURE(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120), PACK(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120), PACK(59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107), Attention Deficit Hyperactivity Disorder (ADHD), Moderate to Severe Binge Eating Disorder (BED) in adults, Capsules 10 mg: pink body/pink cap (imprinted with S489 and 10 mg), Capsules 20 mg: ivory body/ivory cap (imprinted with S489 and 20 mg), Capsules 30 mg: white body/orange cap (imprinted with S489 and 30 mg), Capsules 40 mg: white body/blue green cap (imprinted with S489 and 40 mg), Capsules 50 mg: white body/blue cap (imprinted with S489 and 50 mg), Capsules 60 mg: aqua blue body/aqua blue cap (imprinted with S489 and 60 mg), Capsules 70 mg: blue body/orange cap (imprinted with S489 and 70 mg), Chewable tablets 10 mg: White to off-white round shaped tablet debossed with '10' on one side and 'S489' on the other, Chewable tablets 20 mg: White to off-white hexagonal shaped tablet debossed with '20' on one side and 'S489' on the other, Chewable tablets 30 mg: White to off-white arc triangular shaped tablet debossed with '30' on one side and 'S489' on the other, Chewable tablets 40 mg: White to off-white capsule shaped tablet debossed with '40' on one side and 'S489' on the other, Chewable tablets 50 mg: White to off-white arc square shaped tablet debossed with '50' on one side and 'S489' on the other, Chewable tablets 60 mg: White to off-white arc diamond shaped tablet debossed with '60' on one side and 'S489' on the other, Known hypersensitivity to amphetamine products or other ingredients of Vyvanse. Dispose of remaining, unused, or expired Vyvanse by a medicine take-back program. Vyvanse is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD). In a study in which juvenile dogs received lisdexamfetamine dimesylate for 6 months beginning at 10 weeks of age, decreased bodyweight gain was seen at all doses tested (2, 5, and 12 mg/kg/day, which are approximately 0.5, 1, and 3 times the maximum recommended human daily dose on a mg/m2 basis for a child). Children should have their height and weight checked often while taking Vyvanse. The maximum recommended dose in ESRD (GFR < 15 mL/min/1.73 m2) patients is 30 mg/day [see Clinical Pharmacology (12.3)]. All Vyvanse dose groups were superior to placebo in the primary efficacy outcome (Study 7 in Table 7). Patients with cardiovascular risk factors other than obesity and smoking were excluded. Treatment for ADHD also generally involves behavioral therapies. Acheté Générique 50 mg vyvanse Finlande vyvanse 100 mg szedese acheter vyvanse en pharmacie forum. Signs and symptoms of CNS stimulant abuse may include increased heart rate, respiratory rate, blood pressure, and/or sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss of coordination, tremors, flushed skin, vomiting, and/or abdominal pain. Vyvanse hasn’t been tested in children under age 6 who have ADHD, or in children under age 18 with binge-eating disorder. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy [see Warnings and Precautions (5.1, 5.2), and Drug Abuse and Dependence (9.2, 9.3)]. A study was conducted with amphetamine (d- to l- enantiomer ratio of 3:1) in which pregnant rats received daily oral doses of 2, 6, and 10 mg/kg from gestation day 6 to lactation day 20. Careful observation for digital changes is necessary during treatment with stimulants. Vyvanse and fatigue. Did ADHD traits keep humans alive during the evolutionary hunter-gatherer…, Learn how to recognize adult ADHD and manage its symptoms with these ADHD tips for adults. Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant, is for once-a-day oral administration. Chewable Tablet Inactive Ingredients: colloidal silicon dioxide, croscarmellose sodium, guar gum, magnesium stearate, mannitol, microcrystalline cellulose, sucralose, artificial strawberry flavor. Careful follow-up for weight in children ages 6 to 12 years who received Vyvanse over 12 months suggests that consistently medicated children (i.e. Safety and efficacy in pediatric patients below the age of 6 years have not been established. In this study, patients were randomized in a 1:1:1:1 ratio to a daily morning dose of Vyvanse (30 mg/day, 50 mg/day or 70 mg/day) or placebo for a total of four weeks of treatment. Do not breastfeed while taking Vyvanse. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Vyvanse initiation or dosage increase. Vyvanse may be administered in one of the following ways: Information for Vyvanse chewable tablets: Vyvanse capsules can be substituted with Vyvanse chewable tablets on a unit per unit/ mg per mg basis (for example, 30 mg capsules for 30 mg chewable tablet) [see Clinical Pharmacology (12.3)]. de la diarrhée;. Effets secondaires courants . Intuniv et vyvanse TDAH : L'efficacité des médicaments Agence Science-Press . A double-blind, randomized, placebo-controlled, parallel-group study (Study 4) was conducted in adolescents ages 13 to 17 years (N=314) who met DSM-IV criteria for ADHD. A significant difference in patient behavior, based upon the average of investigator ratings on the SKAMP-DS across the 8 assessments were observed between patients when they received Vyvanse compared to patients when they received placebo (Study 2 in Table 7). Vyvanse - Utilisations, Effets secondaires, Interactions . In addition to treating ADHD, Vyvanse is approved to treat binge eating disorder. This drug is a federally controlled substance, which means it has the potential for abuse or dependence. Amphetamines, such as Vyvanse, cause vasoconstriction and thereby may decrease placental perfusion. Les effets secondaires courants de Vyvanse comprennent la diarrhée, perte d'appétit, perte de poids, la bouche sèche, constipation, transpiration, vertiges, irritabilité légère, des maux de tête, agitation et difficulté à dormir. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. CNS stimulants, including Vyvanse, other amphetamines, and methylphenidate-containing products have a high potential for abuse. The 50 and 70 mg/day doses were statistically superior to placebo on the primary endpoint. The chemical structure is: Lisdexamfetamine dimesylate is a white to off-white powder that is soluble in water (792 mg/mL). Following a 3-week open-label dose optimization with Adderall XR®, patients were randomly assigned to continue their optimized dose of Adderall XR (10 mg, 20 mg, or 30 mg), Vyvanse (30 mg, 50 mg, or 70 mg), or placebo once daily in the morning for 1 week each treatment. Elle exerce une action qui influe sur l'équilibre des substances chimiques naturelles du cerveau. Dans la plupart des cas, le TDAH se traite à l’aide de médicaments stimulants. atomoxetine, desipramine, venlafaxine), CYP2C19 (e.g. On les a appelé des psychostimulants parce que lorsqu’on les donne aux rats, on voit qu’ils se mettent à bouger énormément. In vitro data demonstrated that red blood cells have a high capacity for metabolism of lisdexamfetamine; substantial hydrolysis occurred even at low hematocrit levels (33% of normal). Monitor frequently and adjust or use alternative therapy based on clinical response. Je pense aujourd’hui que c’est la dépression qui provoquait l’hyperphagie, et non l’Effexor. Le TDAH peut entraîner des difficultés sur bien des plans : scolaire, comportemental, relationnel, et autres. General information about the safe and effective use of Vyvanse. Call your doctor right away if you have any new or worsening mental symptoms or problems while taking Vyvanse, especially: Tell your doctor if you have numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes. Do not store the yogurt, water, or orange juice after it has been mixed with Vyvanse. You may report side effects to FDA at 1-800-FDA-1088. In addition, no dose adjustment of guanfacine or venlafaxine is needed when Vyvanse is co-administered [see Clinical Pharmacology (12.3)]. Endpoint was defined as the last post-randomization treatment week (i.e. Patients Ages 13 to 17 Years Old with ADHD. These are not all the possible side effects of Vyvanse. Dose-related decreases in food consumption, bodyweight gain, and crown-rump length were seen; after a four-week drug-free recovery period, bodyweights and crown-rump lengths had significantly recovered in females but were still substantially reduced in males. Store Vyvanse in a safe place, like a locked cabinet. Generic Name: lisdexamfetamine dimesylate Il existe des alternatives émergentes, hors AMM, à proposer dans le cadre d'une ATU - le Strattera et le Vyvanse. Take Vyvanse exactly as your doctor tells you to take it. Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, guar gum, magnesium stearate, mannitol, microcrystalline cellulose, sucralose, artificial strawberry flavor. Acute administration of high doses of amphetamine (d- or d,l-) has been shown to produce long-lasting neurotoxic effects, including irreversible nerve fiber damage, in rodents. heart problems, heart defects, high blood pressure, mental problems including psychosis, mania, bipolar illness, or depression. Vyvanse comes in capsules or chewable tablets. Manifestations of amphetamine overdose include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. All patients receiving Vyvanse were initiated on 30 mg for the first week of treatment. After an 8-hour fast, the AUC for dextroamphetamine following oral administration of lisdexamfetamine dimesylate in solution and as intact capsules were equivalent. Tell your doctor if you have a history of drug or alcohol abuse. Physical dependence (a state of adaptation manifested by a withdrawal syndrome produced by abrupt cessation, rapid dose reduction, or administration of an antagonist) may occur in patients treated with CNS stimulants including Vyvanse. Les effets secondaires potentiels de l’un ou l’autre de ces médicaments pour la perte de poids semblent l’emporter sur les avantages potentiels. Do not start any new medicine while taking Vyvanse without talking to your doctor first. Efficacy assessments were conducted at 1, 2, 3, 4.5, 6, 8, 10, and 12 hours post-dose using the Swanson, Kotkin, Agler, M.Flynn, and Pelham Deportment scores (SKAMP-DS), a 4-item subscale of the SKAMP with scores ranging from 0 to 24 points that measures deportment problems leading to classroom disruptions. Pharmacokinetic studies after oral administration of lisdexamfetamine dimesylate have been conducted in healthy adult (capsule and chewable tablet formulations) and pediatric (6 to 12 years) patients with ADHD (capsule formulation). Patients assigned to the 50 mg and 70 mg dose groups were titrated by 20 mg per week until they achieved their assigned dose. hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in 0.1% of CNS stimulant-treated patients compared to 0% in placebo-treated patients. Subjects from both studies on Vyvanse had a statistically significantly greater reduction from baseline in mean number of binge days per week at Week 12. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Si la molécule ne vous va pas, ce ne sera pas dans l’absence d’efficacité que vous le verrez, ce sera avec des signes tels que : anxiété, irritabilité, agressivité… ou encore avec les effets secondaires, maux de ventre, maux de tête, étourdissement, perte importante d’appétit ou de sommeil, etc. Clinical studies of Vyvanse did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Safety and effectiveness have been established in pediatric patients with ADHD ages 6 to 17 years [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1)]. A significantly lower proportion of treatment failures occurred among Vyvanse subjects (15.8%) compared to placebo (67.5%) at endpoint of the randomized withdrawal period. Toxic symptoms may occur idiosyncratically at low doses. Adverse reactions reported in the pooled controlled trials in adult patients (Study 11 and 12) treated with Vyvanse or placebo are presented in Table 4 below. Lisdexamfetamine dimesylate had no apparent effects on embryo-fetal morphological development or survival when administered orally to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 40 and 120 mg/kg/day, respectively. Advise women not to breastfeed if they are taking Vyvanse [see Use in Specific Populations (8.2)]. Additional increases to 70 mg/day were made as tolerated and clinically indicated. A significant difference in patient behavior, based upon the average of investigator ratings on the SKAMP-Deportment scores across all 7 assessments conducted at 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours post-dose, were observed between patients when they received Vyvanse compared to patients when they received placebo (Study 3 in Table 7, Figure 4). If serotonin syndrome occurs, discontinue Vyvanse and the concomitant serotonergic drug(s), selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort. Vyvanse capsules contain 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg of lisdexamfetamine dimesylate (equivalent to 5.8 mg, 11.6 mg, 17.3 mg, 23.1 mg, 28.9 mg, 34.7 mg, and 40.5 mg of lisdexamfetamine). Vyvanse 100 mg produced significantly less "Drug Liking Effects" as measured by the Drug Rating Questionnaire-Subject score, compared to d-amphetamine 40 mg; and 150 mg of Vyvanse demonstrated similar "Drug-Liking Effects" compared to 40 mg of d-amphetamine and 200 mg of diethylpropion. Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e. before swallowing. Il a aussi d’énormes troubles d’apprentissage. Instruct patients that Vyvanse can cause elevations of their blood pressure and pulse rate and they should be monitored for such effects. Be sure to tell your doctor if you experience side effects. For both studies, a binge day was defined as a day with at least 1 binge episode, as determined from the subject's daily binge diary. Urinary acidifying agents can lower blood levels and efficacy of amphetamines. Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included abdominal pain upper, dry mouth, weight decreased, dizziness, somnolence, logorrhea, chest pain, anger and hypertension. Instruct patients to find out how Vyvanse will affect them before engaging in potentially dangerous activities [see Adverse Reactions (6.1, 6.2)]. Effects of other drugs on the exposures of dextroamphetamine are summarized in Figure 2. We explain the process of being diagnosed with ADHD, what to expect, and…. Because of the potential for serious adverse reactions in nursing infants, including serious cardiovascular reactions, blood pressure and heart rate increase, suppression of growth, and peripheral vasculopathy, advise patients that breastfeeding is not recommended during treatment with Vyvanse. Adverse reactions reported in the controlled trials in pediatric patients ages 6 to 12 years (Study 1), adolescent patients ages 13 to 17 years (Study 4), and adult patients (Study 7) treated with Vyvanse or placebo are presented in Tables 1, 2, and 3 below. Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports, Known hypersensitivity to amphetamine products or other ingredients of Vyvanse, Hypertensive Crisis When Used Concomitantly with Monoamine Oxidase Inhibitors, Peripheral Vasculopathy, including Raynaud's phenomenon, Three short-term trials in children (6 to 12 years, Studies 1, 2, 3), One short-term trial in adolescents (13 to 17 years, Study 4), One short-term trial in children and adolescents (6 to 17 years, Study 5), Two short-term trials in adults (18 to 55 years, Studies 7, 8), Two randomized withdrawal trials in children and adolescents (6 to 17 years, Study 6), and adults (18 to 55 years, Study 9), One randomized trial in adults (18 to 55 years, Study 10), Two short-term trials in adults (18 to 55 years, Studies 11 and 12), One randomized withdrawal study in adults (18 to 55 years, Study 13), Vyvanse capsules 10 mg: pink body/pink cap (imprinted with S489 and 10 mg), bottles of 100, NDC 59417-101-10, Vyvanse capsules 20 mg: ivory body/ivory cap (imprinted with S489 and 20 mg), bottles of 100, NDC 59417-102-10, Vyvanse capsules 30 mg: white body/orange cap (imprinted with S489 and 30 mg), bottles of 100, NDC 59417-103-10, Vyvanse capsules 40 mg: white body/blue green cap (imprinted with S489 and 40 mg), bottles of 100, NDC 59417-104-10, Vyvanse capsules 50 mg: white body/blue cap (imprinted with S489 and 50 mg), bottles of 100, NDC 59417-105-10, Vyvanse capsules 60 mg: aqua blue body/aqua blue cap (imprinted with S489 and 60 mg), bottles of 100, NDC 59417-106-10, Vyvanse capsules 70 mg: blue body/orange cap (imprinted with S489 and 70 mg), bottles of 100, NDC 59417-107-10, Vyvanse chewable tablets 10 mg: White to off-white round shaped tablet debossed with '10' on one side and 'S489' on the other, bottles of 100, NDC 59417-115-01, Vyvanse chewable tablets 20 mg: White to off-white hexagonal shaped tablet debossed with '20' on one side and 'S489' on the other, bottles of 100, NDC 59417-116-01, Vyvanse chewable tablets 30 mg: White to off-white arc triangular shaped tablet debossed with '30' on one side and 'S489' on the other, bottles of 100, NDC 59417-117-01, Vyvanse chewable tablets 40 mg: White to off-white capsule shaped tablet debossed with '40' on one side and 'S489' on the other, bottles of 100, NDC 59417-118-01, Vyvanse chewable tablets 50 mg: White to off-white arc square shaped tablet debossed with '50' on one side and 'S489' on the other, bottles of 100, NDC 59417-119-01, Vyvanse chewable tablets 60 mg: White to off-white arc diamond shaped tablet debossed with '60' on one side and 'S489' on the other, bottles of 100, NDC 59417-120-01. Less commonly reported adverse reactions (less than 1% or less than twice rate of placebo) included increased heart rate, headache, abdominal pain upper, dyspnea, rash, insomnia, irritability, feeling jittery and anxiety. Le Ritalin dure 4 h et doit être donné le matin et le midi, ce qui le rend moins intéressant. Compared to 60 mg Vyvanse capsule, exposure (Cmax and AUC) to lisdexamfetamine was about 15% lower. Higher doses were associated with greater weight loss with 4 weeks of treatment. It is not approved for use as a weight l… Dosage may be adjusted in increments of 10 mg or 20 mg at approximately weekly intervals up to maximum dose of 70 mg/day [see Clinical Studies (14.1)]. Subjects were treated with open-label Vyvanse for at least 26 weeks prior to being assessed for entry into the randomized withdrawal period. Increase dose based on clinical response. Pour d’autres conseils sur la gestion des effets secondaires courants, consulte notre document Gestion des stimulants chez les … Last updated on Oct 1, 2019. If clinically warranted, consider initiating Vyvanse with lower doses, monitoring patients for the emergence of serotonin syndrome during drug initiation or titration, and informing patients of the increased risk for serotonin syndrome. How soon for Vyvanse to start working and how long does it last? In addition, adverse effects on reproductive performance were observed in pups whose mothers were treated with amphetamine.